NCT05026983 2026-04-16
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
9 trialsNCT05286788 2026-04-08
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Nationwide Children's Hospital
Phase 2 Recruiting
NCT04741997 2026-03-02
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Recruiting
NCT04903119 2026-02-13
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
University of Kentucky
Phase 1 Recruiting
NCT03991819 2025-12-05
BiniPembro
University Health Network, Toronto
Phase 1 Recruiting
NCT06887088 2025-10-01
ENCEFALO
Grupo Español Multidisciplinar de Melanoma
Phase 2 Recruiting
NCT04598009 2025-09-03
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
University of California, San Francisco
Phase 2 Recruiting
NCT05615818 2025-04-23
SAFIR-ABC10
UNICANCER
Phase 3 Recruiting
NCT03563729 2023-07-13
MEMBRAINS
Herlev Hospital
Phase 2 Recruiting